Keith Kohl of Angel Publishing’s Topline Trader puts the pitch this way: “World Stunned as ‘AI Doctor’ Produces Cures at Light Speed — Now Bill Gates, BlackRock, and Citigroup Are ALL Loading up on This Tiny $5 AI Biotech Stock.”
The promotion promises an AI-powered drug-discovery system that works up to 10 times faster, cuts development costs by up to 80%, and is supposedly on track to produce the first AI drug to enter human trials. It says the offer is available today, with membership limited to 30 new people.
The stock is identified below. Our confidence is 91/100.
What the promotion gave away
The copy gives away an unusually specific trail: a Salt Lake City headquarters in a repurposed mall retail space, a three-week collaboration with NVIDIA, and a supercomputer called BioHive-2. It also points to partnerships with Roche and Bayer, plus a $50 million NVIDIA investment.
The same pitch is also branded as “Golden Age of AI Cures,” “Quantum Quake,” and “The Biggest Boom American Medicine Has Ever Seen.” Those names refer to the same stock promotion, not three separate discoveries.
The stock behind AI Doctor
The stock is Recursion Pharmaceuticals, ticker RXRX. It’s a Salt Lake City biotechnology company built around AI-assisted drug discovery, which matches the promotion’s central “AI Doctor” framing.
The mall clue is the giveaway. Recursion’s official address is at 41 S Rio Grande Street in Salt Lake City, and Fortune reported that the company’s headquarters occupy a converted former Dick’s Sporting Goods space at The Gateway shopping center. That is a much sharper fingerprint than “tiny AI biotech,” a phrase that could fit half the sector.
The NVIDIA trail seals it. Fortune reported that NVIDIA and Recursion employees spent three weeks building BioHive-2 in a Salt Lake City data center. Recursion’s own announcements describe the NVIDIA-powered machine as biopharma’s most powerful supercomputer, while the company’s July 2023 announcement confirms NVIDIA’s $50 million investment. Recursion’s 10-K and partners page also list the Bayer and Roche-Genentech collaborations.
Every claim, checked
The claim-by-claim check below separates what Recursion’s 10-K, official announcements, market data, and ownership filings support from what the sales copy adds on top. Real ingredients are present, but several of the headline flourishes need trimming.
| The promotion claims | Verdict | What we found |
|---|
| This tiny $5 AI biotech stock | Overstated | Public reporting shows RXRX around $2.98-$3.01, while the proposed answer's market data was $3.335. That is well below $10 but not approximately $5. |
| This tiny $5 AI biotech stock | Checks out | market data reports market capitalization of approximately $1.69 billion; the company profile classifies Recursion as a biotechnology company, making 'tiny' reasonable relative to large pharmaceutical companies. |
Claims the record contradicts
“The firm is currently on track to have the first AI drug ever to enter human clinical trials” — Search results citing Fortune report that at least 75 drugs or vaccines from AI-first companies had already entered clinical trials by January 2024. Recursion's REC-4881 is described in company materials as the first clinical proof-of-concept for the Recursion platform, not the first AI drug ever to enter human trials.
Where the pitch outran the record
“This tiny $5 AI biotech stock” — Public reporting shows RXRX around $2.98-$3.01, while the proposed answer's market data was $3.335. That is well below $10 but not approximately $5. “The company's system finds potential new cures” — Recursion's official mission describes identifying 'hit candidates' and potential medicines, not finding cures. Its filing describes preclinical and clinical drug candidates rather than cures.
“reduces development costs by up to 80%” — Recursion's official mission supports major early-discovery savings, saying candidates can be identified for thousands of dollars rather than millions. The promotion broadens that early-stage claim into an 80% reduction in overall development costs; the exact company-wide figure was not established.
“The firm has inked partnership deals with giants like Bristol-Myers Squibb” — Search results state that the BMS relationship was launched in 2019 by Exscientia and Celgene, which BMS later acquired. Exscientia subsequently merged into Recursion, so the combined company inherited the relationship, but this was not a direct original Recursion deal.
“The firm has inked partnership deals with giants like Merck”
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
About that deadline
The promotion says the offer is available today and membership is limited to 30 new members. We received it on one day, August 3, 2026, which is too thin a record to say whether the deadline rolls.
There’s also no stated link to a checkable event such as an earnings date, FDA decision, index rebalance, or IPO lockup expiry. For now, “today” is simply the deadline attached to joining the newsletter offer.
Is it actually worth owning?
Recursion is a real AI drug-discovery company with clinical and preclinical programs, major pharmaceutical partnerships, and a genuine NVIDIA relationship. But its own materials talk about hit candidates and potential medicines, not cures. “AI Doctor” is a memorable label; it isn’t a clinical result.
The market-cap figure is approximately $1.69 billion, while market data put the shares around $2.98 to $3.01 in the check behind this review, not approximately $5. The growth case is a bet that Recursion’s platform and partnerships can turn a broad pipeline into successful medicines. The real risk is ordinary biotech risk: candidates can fail, timelines can stretch, and the company may need more capital before the platform produces commercial returns. Read our full workup before treating institutional holdings or a historic NVIDIA investment as proof of a finished drug.
How confident are we? 91 out of 100. We identified Recursion Pharmaceuticals, Inc. (RXRX) from the promotion's own clues and checked 24 of its claims against filings, earnings calls, ownership records, market data and public reporting. This is our analysis, not the publisher's disclosure — we have no relationship with them.
